Development of a Tumor-Targeting MR Contrast Agent Using the High-Affinity Folate Receptor

Abstract

This new agent accumulates in tumors expressing hFR. These results do not differentiate between active and passive targeting mechanisms. Receptor-negative tumors suggest a mechanism other than a nonspecific blood pool effect.